Transenterix Inc (TRXC) Short Interest Update

Transenterix Inc (NYSEAMERICAN:TRXC) was the recipient of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 17,250,155 shares, a growth of 6.5% from the January 12th total of 16,200,995 shares. Based on an average daily trading volume, of 2,000,529 shares, the short-interest ratio is currently 8.6 days. Currently, 11.7% of the company’s stock are sold short.

In other news, CFO Joseph P. Slattery sold 529,609 shares of Transenterix stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $2.80, for a total value of $1,482,905.20. Following the sale, the chief financial officer now directly owns 440,974 shares in the company, valued at $1,234,727.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Joseph P. Slattery sold 333,000 shares of Transenterix stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $2.93, for a total transaction of $975,690.00. Following the completion of the sale, the chief financial officer now owns 440,974 shares in the company, valued at $1,292,053.82. The disclosure for this sale can be found here.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in Transenterix during the fourth quarter worth $109,000. BlackRock Inc. increased its holdings in Transenterix by 157.3% during the fourth quarter. BlackRock Inc. now owns 1,760,266 shares of the medical instruments supplier’s stock worth $3,397,000 after buying an additional 1,076,133 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Transenterix by 94.0% during the fourth quarter. Bank of New York Mellon Corp now owns 119,584 shares of the medical instruments supplier’s stock worth $231,000 after buying an additional 57,944 shares during the last quarter. Raymond James Financial Services Advisors Inc. acquired a new position in Transenterix during the fourth quarter worth $113,000. Finally, Ladenburg Thalmann Financial Services Inc. increased its holdings in Transenterix by 87.8% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 79,150 shares of the medical instruments supplier’s stock worth $113,000 after buying an additional 37,000 shares during the last quarter.

A number of analysts have recently issued reports on TRXC shares. Ladenburg Thalmann Financial Services set a $5.00 price objective on shares of Transenterix and gave the company a “buy” rating in a report on Friday, October 20th. Stifel Nicolaus reiterated a “buy” rating and issued a $4.00 price objective (up from $3.75) on shares of Transenterix in a report on Monday, October 30th. BTIG Research reiterated a “hold” rating on shares of Transenterix in a report on Monday, December 18th. Finally, Zacks Investment Research downgraded shares of Transenterix from a “hold” rating to a “sell” rating in a report on Thursday, January 11th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $2.61.

Shares of Transenterix (NYSEAMERICAN TRXC) traded down $0.04 on Friday, reaching $1.33. 2,281,876 shares of the company were exchanged, compared to its average volume of 2,223,832. The firm has a market capitalization of $282.92, a P/E ratio of -2.21 and a beta of 2.20. Transenterix has a fifty-two week low of $0.45 and a fifty-two week high of $5.00.

Transenterix (NYSEAMERICAN:TRXC) last issued its earnings results on Thursday, November 9th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.09). Transenterix had a negative net margin of 21,045.36% and a negative return on equity of 137.69%.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://sportsperspectives.com/2018/02/09/transenterix-inc-trxc-short-interest-update.html.

Transenterix Company Profile

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

Receive News & Ratings for Transenterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply